The present invention relates to a neurodegenerative disease therapeutic agent, and, more specifically, provides a composition containing, as an active ingredient, an ALK (anaplastic lymphoma kinase) activity or expression inhibiting substance in order to treat a degenerative brain disease caused by the phosphorylation or coagulation of tau proteins.